An interventional study of Composite Immune Risk Score Stratification Notification Group in Transplant-Related Disorder, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Recruiting at 1 site in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
In this prospective randomized controlled trial of umbilical cord blood hematopoietic stem cell transplant recipients, post-transplant immune data will be collected from two groups. A composite immune risk score will be used to assess immune reconstitution for risk stratification and analyze its associations with clinical prognostic endpoints.
Institute of Hematology & Blood Diseases Hospital, China is the lead sponsor of 413 studies on the registry; 292 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Attending physicians will receive immune reconstitution risk stratification results of patients calculated by the composite immune risk score model to guide patient health monitoring.
Behavioral: Composite Immune Risk Score Stratification Notification Group
No risk stratification results of patients from the composite immune risk score model will be provided to attending physicians. Patients receive standard routine care.
Attending physicians will receive immune reconstitution risk stratification results of patients calculated by the composite immune risk score model to guide patient health monitoring.
Frequency of infection-related laboratory testing (blood culture, pathogen PCR, NGS)
Defined as the count of infection-related laboratory tests (blood culture, pathogen PCR, pathogen NGS) for each patient within 6 months after umbilical cord blood transplantation. Test counts are extracted from electronic medical records.
Time frame: 6 months post-transplant
Number of medication adjustments intended to accelerate immune reconstitution or enhance infection prophylaxis
Time frame: 6 months post-transplant
Number of return visits
Time frame: 6 months post-transplant
Frequency of infection-related laboratory testing (blood culture, pathogen PCR, NGS)
Defined as the count of infection-related laboratory tests (blood culture, pathogen PCR, pathogen NGS) for each patient within 1 year after umbilical cord blood transplantation. Test counts are extracted from electronic medical records.
Time frame: 1 year post-transplant
Number of medication adjustments intended to accelerate immune reconstitution or enhance infection prophylaxis
Time frame: 1 year post-transplant
Number of return visits
Time frame: 1 year post-transplant
Immune reconstitution status (quantity of T, B, NK cells and other immune subsets, and T cell clonal diversity)
Defined as the quantity of T cells, B cells, NK cells and other immune subsets measured by flow cytometry, and T cell clonal diversity assessed by TCR repertoire sequencing at scheduled time points. Data are extracted from electronic medical records.
Time frame: at 4, 6, 9 and 12 months post-transplant
Infection rate
Time frame: at 6, 9 and 12 months post-transplant
Incidence of chronic GVHD
Time frame: at 6, 9 and 12 months post-transplant
Relapse rate
Time frame: at 6, 9 and 12 months post-transplant
Survival
Time frame: at 6, 9 and 12 months post-transplant
Hospitalization rate
Time frame: at 6, 9 and 12 months post-transplant
Outpatient rate
Time frame: at 6, 9 and 12 months post-transplant
Started Oct 2026 (actual). Primary completion is estimated for May 2027, 6 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Institute of Hematology & Blood Diseases Hospital, China →